Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Omiganan
Overview
Omiganan is a synthetic 12-amino acid cationic antimicrobial peptide derived from indolicidin, a naturally occurring peptide from bovine neutrophils. It acts by disrupting microbial membranes and demonstrates activity against bacteria, fungi, and some viruses.
Mechanism of Action
Omiganan was developed as a topical agent to prevent catheter-related bloodstream infections through its broad-spectrum antimicrobial properties. Its small size and potent activity made it a candidate for preventing biofilm formation on medical devices.
Research Summary & Key Findings
Phase III trials evaluated omiganan as a catheter site antiseptic gel but did not demonstrate statistically significant reduction in catheter-related bloodstream infections compared to standard care. The FDA issued a Complete Response Letter in 2007 citing insufficient efficacy data. Subsequent development has focused on rosacea and other dermatologic indications, with Phase II trials conducted in acne vulgaris.
Clinical Status
Omiganan is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
Administration Routes
References
Primary literature
- PubMed: "Omiganan"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Omiganan"
Registered interventional and observational studies, including status and phase.
- PubChem: "Omiganan"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Antimicrobial
Enfuvirtide (Fuzeon)
FDA ApprovedA 36-amino acid synthetic peptide that inhibits HIV-1 entry into CD4+ T-cells by blocking the gp41-mediated membrane fus...
View detailsMagainin 2
Research PhaseMagainin 2 is a 23-amino acid antimicrobial peptide originally isolated from the skin of the African clawed frog Xenopus...
View detailsPexiganan (MSI-78)
In Clinical TrialsPexiganan is a 22-amino acid synthetic analog of magainin 2 designed to enhance antimicrobial potency and proteolytic st...
View detailsIseganan (IB-367)
InvestigationalIseganan is a 17-amino acid synthetic analog of protegrin, a naturally occurring antimicrobial peptide found in porcine ...
View detailsNo lawful pathway today
Omiganan is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.